Bristol-Myers Squibb (NYSE:BMY) - Cotización, noticias y análisis

Resumen de acción BMY

Bristol-Myers Squibb Company descubre, desarrolla, licencia, fabrica, comercializa, distribuye y vende productos biofarmacéuticos en todo el mundo.

Acerca de la empresa

BMY fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	4/6
Past Performance	0/6
Financial Health	3/6
Dividends	5/6

Recompensas

Cotiza un 65.2% por debajo de nuestra estimación de su valor justo

Se prevé un crecimiento anual de los beneficios de 44.31%

Cotiza a buen valor en comparación con empresas similares e industria

Análisis de riesgos

El dividendo de 5.37% no está bien cubierto por los beneficios

Tiene un alto nivel de endeudamiento

Narratives

Beta

Narratives bring a range of perspectives from our community.

Warren

Based on Analyst Price Targets

Expanding Oncology Portfolio and Advancing INDs Promise Bright Future for Revenue Growth and Net Margins

Increased investment in growth brands and successful commercialization of products like Breyanzi hint at significant...

Price at publication US$52.49

View narrative

Updated 18 Mar 2024

Competidores de Bristol-Myers Squibb Company

Zoetis

NYSE:ZTS

US$76.9b

Pfizer

NYSE:PFE

US$157.2b

Johnson & Johnson

NYSE:JNJ

US$357.9b

Merck

NYSE:MRK

US$330.2b

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Bristol-Myers Squibb
Historical stock prices
Current Share Price	US$43.67
52 Week High	US$69.10
52 Week Low	US$43.33
Beta	0.39
1 Month Change	-14.54%
3 Month Change	-10.35%
1 Year Change	-36.24%
3 Year Change	-32.33%
5 Year Change	-6.35%
Change since IPO	1,943.79%

Noticias y actualizaciones recientes

Bristol-Myers Squibb: A Lost Decade?

May 03

Lacklustre Performance Is Driving Bristol-Myers Squibb Company's (NYSE:BMY) Low P/S

Apr 29

Recent updates

Bristol-Myers Squibb: A Lost Decade?

May 03

Lacklustre Performance Is Driving Bristol-Myers Squibb Company's (NYSE:BMY) Low P/S

Apr 29

Bristol-Myers Squibb: Compelling Value From The New Products Portfolio And 4.5% Yield

Mar 07

Bristol-Myers Squibb (NYSE:BMY) Is Due To Pay A Dividend Of $0.60

Mar 07

We Think Bristol-Myers Squibb's (NYSE:BMY) Healthy Earnings Might Be Conservative

Feb 20

Bristol-Myers Squibb Company (NYSE:BMY) Just Released Its Annual Results And Analysts Are Updating Their Estimates

Feb 06

Bristol-Myers Squibb: Massive Discount Spells Opportunity

Feb 04

BMY: Might Be Approaching A Bottom In 2024

Jan 23

Investors Aren't Entirely Convinced By Bristol-Myers Squibb Company's (NYSE:BMY) Earnings

Jan 16

Bristol-Myers Squibb: I Went Looking For Value And Found A 4.63% Yield Also

Jan 10

Bristol-Myers Squibb's Winning Formula: Dividends, M&A, And Innovation

Dec 31

Bristol-Myers Squibb (NYSE:BMY) Has Announced That It Will Be Increasing Its Dividend To $0.60

Dec 26

Bristol Myers Squibb: This Dividend Contender Is A Steal Right Now

Dec 19

Bristol-Myers Squibb: A Nice Deal For This Bargain Pharma Stock

Dec 12

Bristol-Myers Squibb (NYSE:BMY) Is Increasing Its Dividend To $0.60

Dec 11

Bristol-Myers Squibb: The Patent Expiry Challenge

Nov 23

Bristol Myers Squibb: Bright Future Ahead

Nov 17

Bristol-Myers Squibb (NYSE:BMY) Has A Pretty Healthy Balance Sheet

Nov 08

Rentabilidad de los accionistas

	BMY	US Pharmaceuticals	Mercado US
7D	-1.2%	0.3%	3.3%
1Y	-36.2%	12.0%	25.0%

Rentabilidad vs. Industria: BMY obtuvo unos resultados inferiores a los del sector US Pharmaceuticals , que el año pasado arrojó un rendimiento del 9.5%.

Rentabilidad vs. Mercado: BMY obtuvo unos resultados inferiores a los del mercado US, que fue del 21.9% el año pasado.

Volatilidad de los precios

Is BMY's price volatile compared to industry and market?
BMY volatility
BMY Average Weekly Movement	3.6%
Pharmaceuticals Industry Average Movement	10.0%
Market Average Movement	6.1%
10% most volatile stocks in US Market	16.5%
10% least volatile stocks in US Market	3.0%

Precio estable de las acciones: BMY no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de BMY (3%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1887	34,100	Chris Boerner	www.bms.com

Bristol-Myers Squibb Company descubre, desarrolla, licencia, fabrica, comercializa, distribuye y vende productos biofarmacéuticos en todo el mundo. Ofrece productos para enfermedades hematológicas, oncológicas, cardiovasculares, inmunológicas, fibróticas y neurocientíficas. Los productos de la empresa incluyen Eliquis para la reducción del riesgo de ictus/embolia sistémica en la fibrilación auricular no valvular, y para el tratamiento de la TVP/EP; Opdivo para diversas indicaciones contra el cáncer, como el de vejiga, sangre, CCR, cabeza y cuello, CCR, CHC, pulmón, melanoma, MPM, estómago y esófago; Pomalyst/Imnovid para el mieloma múltiple; Orencia para la artritis reumatoide activa y la artritis psoriásica; y Sprycel para el tratamiento de la leucemia mieloide crónica con cromosoma Filadelfia positivo.

Resumen de fundamentos de Bristol-Myers Squibb Company

¿Cómo se comparan los beneficios e ingresos de Bristol-Myers Squibb con su capitalización de mercado?
Estadísticas fundamentales de BMY
Capitalización bursátil	US$89.27b
Beneficios(TTM)	-US$6.15b
Ingresos (TTM)	US$45.53b

1.9x

Ratio precio-ventas (PS)

-14.4x

Ratio precio-beneficio (PE)

¿Está BMY sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de BMY
Ingresos	US$45.53b
Coste de los ingresos	US$10.92b
Beneficio bruto	US$34.62b
Otros gastos	US$40.77b
Beneficios	-US$6.15b

Últimos beneficios comunicados

Mar 31, 2024

Próxima fecha de beneficios

Jul 26, 2024

Beneficios por acción (BPA)	-3.03
Margen bruto	76.03%
Margen de beneficio neto	-13.50%
Ratio deuda/patrimonio	336.7%

¿Cómo se ha desempeñado BMY a largo plazo?

Ver rendimiento histórico y comparativa

Dividendos

5.5%

Rentabilidad actual por dividendo

-78%

Ratio de pagos

Resumen de acción BMY

Recompensas

Análisis de riesgos

Expanding Oncology Portfolio and Advancing INDs Promise Bright Future for Revenue Growth and Net Margins

Competidores de Bristol-Myers Squibb Company

NYSE:ZTS

US$76.9b

NYSE:PFE

US$157.2b

NYSE:JNJ

US$357.9b

NYSE:MRK

US$330.2b

Historial de precios y rendimiento

Noticias y actualizaciones recientes

U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase)

European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer

Bristol-Myers Squibb: A Lost Decade?

Lacklustre Performance Is Driving Bristol-Myers Squibb Company's (NYSE:BMY) Low P/S

CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb's Opdivo (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Recent updates

U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase)

European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer

Bristol-Myers Squibb: A Lost Decade?

Lacklustre Performance Is Driving Bristol-Myers Squibb Company's (NYSE:BMY) Low P/S

CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb's Opdivo (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Is Bristol Myers Squibb A Buy At These Bottom Levels?

Bristol Myers Squibb: Seriously Undervalued At Peak Pessimism (Rating Upgrade)

Consensus EPS estimates fall by 24%

Bristol Myers Squibb Announces KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)

U.S. Fda Approves Bristol Myers Squibb and 2Seventy Bio’S Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy

European Commission Expands Approval of Bristol Myers Squibb’S Reblozyl® (Luspatercept)

Bristol-Myers Squibb Is A Speculative Buy On Price Action (Technical Analysis)

Bristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (Oozanimod) in Patients with Moderate to Severe Active Crohn's Disease

Upcoming dividend of US$0.60 per share

Bristol Myers Squibb to Present Data at the American College of Cardiology Annual Scientific Session 2024

Bristol Myers Squibb’s Abecma (idecabtagene vicleucel) Becomes First CAR T Cell Therapy Approved in the European Union in Earlier Lines for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma

Bristol-Myers Squibb (NYSE:BMY) Is Due To Pay A Dividend Of $0.60

Bristol-Myers Squibb Company, Annual General Meeting, May 07, 2024

Bristol-Myers Squibb Is Not A Buy For Me

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of Karuna Therapeutics, Inc. (NasdaqGM:KRTX) from Capital International Investors, FMR LLC, The Vanguard Group, Inc., T. Rowe Price Group, Inc. (NasdaqGS:TROW) and others.

FDA Advisory Committee Votes in Favor of Bristol-Myers Squibb Company and 2seventy bio, Inc. Abecma for Triple-Class Exposed Multiple Myeloma in Further Lines of Therapy

U.S. FDA Approves Bristol Myers Squibb’s Breyanzi® as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Executive Chairman of the Board exercised options and sold US$3.6m worth of stock

Bristol-Myers Squibb Company to Report Q1, 2024 Results on Apr 25, 2024

U.S. Food and Drug Administration Approves Bristol-Myers Squibb Company's Opdivo

Bristol-Myers Squibb: Compelling Value From The New Products Portfolio And 4.5% Yield

Bristol-Myers Squibb (NYSE:BMY) Is Due To Pay A Dividend Of $0.60

Fourth quarter dividend of US$0.60 announced

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of RayzeBio, Inc. (NasdaqGM:RYZB).

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of RayzeBio, Inc. (NasdaqGM:RYZB).

Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl® (luspatercept) for Treatment of Adults with Transfusion-Dependent Anemia due to Low- to Intermediate-Risk Myelodysplastic Syndromes (MDS)

We Think Bristol-Myers Squibb's (NYSE:BMY) Healthy Earnings Might Be Conservative

Bristol-Myers Squibb Company Announces Management Changes

U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Augtyro (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors

Bristol Myers Squibb Announces Acceptance of U.S. and EU Regulatory Filings for Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Opdivo in Resectable Non-Small Cell Lung Cancer

Bristol-Myers Squibb Company (NYSE:BMY) Just Released Its Annual Results And Analysts Are Updating Their Estimates

Bristol Myers Squibb and 2seventy bio, Inc. Share Update on U.S. FDA Oncologic Drugs Advisory Committee Meeting for Abecma in Triple-Class Exposed Multiple Myeloma Based on KarMMa-3 Study

Bristol-Myers Squibb: Massive Discount Spells Opportunity

Full year 2023 earnings: EPS exceeds analyst expectations

Bristol-Myers Squibb Company Announces Three Regulatory Acceptances from the U.S. Food and Drug Administration (FDA) and Japan’S Ministry of Health, Labour and Welfare (MHLW) for Breyanzi

Bristol Myers Squibb Announces the First Disclosure of Data from the Phase 3 CheckMate -67T Trial

Bristol-Myers Squibb Company Receives Positive Chmp Opinion for Car T Cell Therapy Abecma (Idecabtagene Vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma

Bristol Myers Squibb and Exelixis, Inc. Announce Four-Year Follow-Up Results from the CheckMate -9ER Trial Evaluating Opdivo (cabozantinib)

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of Mirati Therapeutics, Inc. (NasdaqGS:MRTX) from a group of shareholders.

BMY: Might Be Approaching A Bottom In 2024

Bristol Myers Squibb Announces Results from the Phase 3 Randomized Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab)

Bristol Myers Squibb Data At Asco Gu 2024 Showcase Transformative Research in the Treatment of Genitourinary Cancers

Investors Aren't Entirely Convinced By Bristol-Myers Squibb Company's (NYSE:BMY) Earnings

Bristol-Myers Squibb: I Went Looking For Value And Found A 4.63% Yield Also

European Medicines Agency Validates Bristol Bristol-Myers Squibb Company Application for Repotrectinib for the Treatment of Locally Advanced or Metastatic Ros1-Positive Non-Small Cell Lung Cancer and Ntrk-Positive Solid Tumors

Bristol-Myers Squibb's Winning Formula: Dividends, M&A, And Innovation

Upcoming dividend of US$0.60 per share at 4.7% yield

Bristol-Myers Squibb Company (NYSE:BMY) entered into definitive merger agreement to acquire RayzeBio, Inc. (NasdaqGM:RYZB) for $3.8 billion.

Bristol-Myers Squibb (NYSE:BMY) Has Announced That It Will Be Increasing Its Dividend To $0.60

Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive merger agreement to acquire Karuna Therapeutics, Inc. (NasdaqGM:KRTX) for $12.6 billion.

Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive merger agreement to acquire Karuna Therapeutics, Inc. (NasdaqGM:KRTX) for $12.5 billion.

Bristol Myers Squibb: This Dividend Contender Is A Steal Right Now